vilazodone
SMILES | N#Cc1ccc2c(c1)c(CCCCN1CCN(CC1)c1ccc3c(c1)cc(o3)C(=O)N)c[nH]2 |
InChIKey | SGEGOXDYSFKCPT-UHFFFAOYSA-N |
Chemical properties
Hydrogen bond acceptors | 5 |
Hydrogen bond donors | 2 |
Rotatable bonds | 7 |
Molecular weight (Da) | 441.2 |
Drug properties
Molecular type | Small molecule |
Endogenous/Surrogate | Surrogate |
Approved drug | Yes |
Database connections
Bioactivities
Receptor | Activity | Source | |||||||
---|---|---|---|---|---|---|---|---|---|
GTP | Uniprot | Species | Family | Class | Type | Min | Avg | Max | Database |
5-HT1A | 5HT1A | Human | 5-Hydroxytryptamine | A | pKi | 7.55 | 8.7 | 9.7 | ChEMBL |
D2 | DRD2 | Human | Dopamine | A | pKi | 6.18 | 6.18 | 6.18 | ChEMBL |
5-HT1A | 5HT1A | Human | 5-Hydroxytryptamine | A | pKi | 9.7 | 9.7 | 9.7 | Guide to Pharmacology |
5-HT1A | 5HT1A | Human | 5-Hydroxytryptamine | A | pKi | 8.01 | 8.01 | 8.01 | Drug Central |
5-HT7 | 5HT7R | Human | 5-Hydroxytryptamine | A | pKi | 8.27 | 8.27 | 8.27 | Drug Central |
5-HT7 | 5HT7R | Human | 5-Hydroxytryptamine | A | pKi | 5.41 | 5.41 | 5.41 | ChEMBL |
Receptor | Activity | Source | |||||||
---|---|---|---|---|---|---|---|---|---|
GTP | Uniprot | Species | Family | Class | Type | Min | Avg | Max | Database |
5-HT1D | 5HT1D | Rat | 5-Hydroxytryptamine | A | pIC50 | 5.4 | 5.4 | 5.4 | ChEMBL |
5-HT6 | 5HT6R | Rat | 5-Hydroxytryptamine | A | pIC50 | 5.52 | 5.52 | 5.52 | ChEMBL |
D4 | DRD4 | Rat | Dopamine | A | pIC50 | 5.47 | 5.47 | 5.47 | ChEMBL |
5-HT4 | 5HT4R | Rat | 5-Hydroxytryptamine | A | pIC50 | 6.6 | 6.6 | 6.6 | ChEMBL |
D3 | DRD3 | Rat | Dopamine | A | pIC50 | 7.15 | 7.15 | 7.15 | ChEMBL |
5-HT2C | 5HT2C | Rat | 5-Hydroxytryptamine | A | pIC50 | 5.7 | 5.7 | 5.7 | ChEMBL |
5-HT1A | 5HT1A | Rat | 5-Hydroxytryptamine | A | pIC50 | 9.52 | 9.52 | 9.52 | ChEMBL |
5-HT1A | 5HT1A | Human | 5-Hydroxytryptamine | A | pEC50 | 9.1 | 9.65 | 9.92 | ChEMBL |
5-HT1A | 5HT1A | Human | 5-Hydroxytryptamine | A | pIC50 | 9.7 | 9.83 | 9.96 | ChEMBL |
5-HT1A | 5HT1A | Human | 5-Hydroxytryptamine | A | pIC50 | 9.52 | 9.52 | 9.52 | Guide to Pharmacology |
5-HT4 | 5HT4R | Human | 5-Hydroxytryptamine | A | pIC50 | 8.18 | 8.18 | 8.18 | Drug Central |
5-HT4 | 5HT4R | Human | 5-Hydroxytryptamine | A | pIC50 | 6.6 | 6.6 | 6.6 | Guide to Pharmacology |
D2 | DRD2 | Human | Dopamine | A | pIC50 | 8.21 | 8.21 | 8.21 | Drug Central |
D2 | DRD2 | Human | Dopamine | A | pIC50 | 6.18 | 6.18 | 6.18 | Guide to Pharmacology |
D3 | DRD3 | Human | Dopamine | A | pIC50 | 8.15 | 8.15 | 8.15 | Drug Central |
D3 | DRD3 | Human | Dopamine | A | pIC50 | 7.15 | 7.15 | 7.15 | Guide to Pharmacology |
H1 | HRH1 | Human | Histamine | A | pIC50 | 8.19 | 8.19 | 8.19 | Drug Central |
H1 | HRH1 | Human | Histamine | A | pIC50 | 6.5 | 6.5 | 6.5 | Guide to Pharmacology |
5-HT2A | 5HT2A | Rat | 5-Hydroxytryptamine | A | pIC50 | 8.24 | 8.24 | 8.24 | Drug Central |
5-HT6 | 5HT6R | Rat | 5-Hydroxytryptamine | A | pIC50 | 8.26 | 8.26 | 8.26 | Drug Central |
D3 | DRD3 | Rat | Dopamine | A | pIC50 | 8.15 | 8.15 | 8.15 | Drug Central |
5-HT4 | 5HT4R | Rat | 5-Hydroxytryptamine | A | pIC50 | 8.18 | 8.18 | 8.18 | Drug Central |
5-HT2C | 5HT2C | Rat | 5-Hydroxytryptamine | A | pIC50 | 8.24 | 8.24 | 8.24 | Drug Central |
5-HT1A | 5HT1A | Rat | 5-Hydroxytryptamine | A | pIC50 | 8.02 | 8.02 | 8.02 | Drug Central |
5-HT1B | 5HT1B | Rat | 5-Hydroxytryptamine | A | pIC50 | 8.28 | 8.28 | 8.28 | Drug Central |
5-HT1B | 5HT1B | Rat | 5-Hydroxytryptamine | A | pIC50 | 5.3 | 5.3 | 5.3 | ChEMBL |
5-HT1D | 5HT1D | Rat | 5-Hydroxytryptamine | A | pIC50 | 8.27 | 8.27 | 8.27 | Drug Central |
5-HT7 | 5HT7R | Rat | 5-Hydroxytryptamine | A | pIC50 | 8.26 | 8.26 | 8.26 | Drug Central |
5-HT7 | 5HT7R | Rat | 5-Hydroxytryptamine | A | pIC50 | 5.52 | 5.52 | 5.52 | ChEMBL |
D4 | DRD4 | Rat | Dopamine | A | pIC50 | 8.26 | 8.26 | 8.26 | Drug Central |
D2 | DRD2 | Rat | Dopamine | A | pIC50 | 8.21 | 8.21 | 8.21 | Drug Central |
D2 | DRD2 | Rat | Dopamine | A | pIC50 | 6.18 | 6.18 | 6.18 | ChEMBL |